Par Pharma Seeks To Void Merck Diabetes Drug Patent
Par Pharmaceutical Inc. asked a New Jersey federal court on Friday to invalidate the patent backing Merck's Janumet XR so it can begin to market a generic equivalent of the Type...To view the full article, register now.
Already a subscriber? Click here to view full article